Clinical Trial Update: A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial to evaluate the safety and efficacy of XER-001 (amifostine delivered nasoduodenally) in combination with stereotactic body radiotherapy for lo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• XER-001 (amifostine)

Snippet

Sponsor: Xerient Pharma | Conditions: Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreas Cancer | Phase 1, Phase 2 | Status: RECRUITING